Manchester College School of Pharmacy seeks new dean
NORTH MANCHESTER, Ind. — Manchester College is looking for a new leader for its pharmacy school, the private university’s president said Tuesday.
The school’s vice president and founding dean, Philip Medon, has resigned for health-related reasons, prompting the university to launch a nationwide search for a new dean. Medon joined the school last year. The school currently has 23 faculty and offers a four-year professional doctoral program. Classes are set to begin in August 2012.
"We are grateful that dean Medon has led the School of Pharmacy through several significant stages in its growth since his arrival in 2010," university president Jo Young Switzer said. "He has hired an exceptional team of faculty and administrators, and the accreditation agency has expressed confidence with the leadership transition plan we have put in place."
Click here to see the school’s website.
MedPro Rx makes Triangle Business Journal’s fast-growing companies list
RALEIGH, N.C. — The Triangle Business Journal has named MedPro Rx to its list of the fastest-growing companies in the North Carolina Research Triangle for the fourth consecutive year, the specialty pharmacy provider said Monday.
MedPro Rx said it had ranked No. 28 on the journal’s 2011 Fast 50 Award list, evaluated by PricewaterhouseCoopers. The company ranked No. 1 in 2008, No. 5 in 2009 and No. 16 in 2010.
"I am deeply gratified that MedPro Rx has received yet another Fast 50 award," president Nancy McFarlane said. "This reflects the commitment of our staff to provide top service to our customers and make sure that we accommodate all of their needs as best as possible."
Amgen drug reduces risk of prostate cancer spreading to bones, study finds
THOUSAND OAKS, Calif. — A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.
Published in The Lancet, the phase-3 "147 study" evaluated Xgeva (denosumab) in men with nonmetastatic, castration-resistant prostate cancer, also known as CRPC. The study "significantly prolonged" survival without bone metastasis, delayed time to bone metastasis and reduced the risk of symptomatic bone metastasis. The company has filed a regulatory approval application with the Food and Drug Administration seeking approval for Xgeva to reduce the risk of CRPC spreading to the bones.
"The prevention of bone metastases is a major unmet medical need for men with castration-resistant prostate cancer," Massachusetts General Hospital Cancer Center medical professor Matthew Smith said. "The more than four-month increase in bone metastasis-free survival with Xgeva treatment is a clinically significant finding that has the potential to improve the management of men living with prostate cancer."